Pilot studies have been conducted by Ibáñez’ group in AYAs with PCOS and without obesity, leading to the identification of a treatment that consists of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), acting through different pathways] and one mixed anti-androgen and anti-mineralocorticoid [spironolactone (SPI)], also acting as BAT activator and thus as driver of energy expenditure. Here, INS is linked to polycystic ovary syndrome.